Fig. 2
Summary of the essential medicines for rheumatic diseases in children and young people on NEMLs in African countries. The number of countries in which these medicines are listed are indicated in brackets. DMARDs: disease-modifying anti-rheumatic drugs; WHO EML: World Health Organisation Essential Medicines List; WHO EMLc: World Health Organisation Essential Medicines List for children. Conventional synthetic DMARDs may include methotrexate (33), and/or hydroxychloroquine (19), chloroquine (13), azathioprine (24), penicillamine (10), sulfasalazine (26); TNFi: tumour necrosis factor inhibitors may include adalimumab (4), and/or etanercept (6), infliximab (4), certolizumab pegol (2), golimumab (2). The additional medicines not on the WHO EML most commonly included ciclosporin (15), cyclophosphamide (10), mycophenolate mofetil (10), rituximab (5) leflunomide (5), tacrolimus (5), triamcinolone acetonide (3) abatacept (2) and tocilizumab (2). Anakinra was only listed in Libya, while belimumab and tofacitinib were only listed in Ghana